Profound Medical

Profound Medical Corp. is a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image-guided ablation of diseased tissue. Its lead product, TULSA-PRO, combines real-time MRI, robotically driven transurethral ultrasound and closed-loop temperature feedback to ablate physician-defined regions of the prostate, and its Sonalleve platform combines real-time MRI thermometry for the treatment of uterine fibroids, adenomyosis, palliative bone-metastasis pain and benign tumours. The company reported preliminary third-quarter 2026 revenue of $9.8–10.0 million, roughly 45–47% above analyst consensus.